CG Oncology Corp (CGON) - Market Capitalization to Book Value Ratio
This daily price chart for CG Oncology, Inc. (CGON) on GURU.Markets captures the 5.48 metric. The biopharma project's management is effectively managing shareholder expectations following its IPO. The business focuses on bladder tumor immunotherapy for clinics, assisting patients with treatment resistance. The technical infrastructure includes certified facilities that are regularly updated to produce drugs for clinical trials.
%20Market%20Cap%20to%20Net%20Assets%20Ratio&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_CGON_-_CG-Oncology-Inc._-_Market-Cap-to-Net-Assets-Ratio "CG Oncology Corp (CGON) Market Capitalization to Book Value Ratio: for the period 02/21/2024 - 10/30/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns and data insights for company CG Oncology Inc (CGON)
- market value and analyst target forecast:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and liquidity details:
Total Debt to Capital CG Oncology, Inc.|CGON - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital CG Oncology Corp|CGON - Company Cumulative Debt|Debt to Book Capitalization Ratio CG Oncology Corp|CGON - Company Long-Term Loans and Borrowings|Company Current Liabilities CG Oncology|Quick Ratio cgoncology.com
- earnings and valuation multiples indicators:
Comprehensive company analysis:CG Oncology, Inc.
The stability of CG Oncology, Inc. (CGON) is based on the unique potential of oncolytic virus bioengineering, which makes the ratio of market capitalization to book value an indicator of the market premium for scientific innovation. This chart compares current market value with net assets, where a steady trend confirms a fair valuation of intellectual capital, while a prolonged decline signals a risk of operating margin compression.
Who CG Oncology, Inc. competes with
BeiGene Ltd (ONC) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio HALO|RVMD (Revolution Medicines, Inc.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Ascentage Pharma Group International (AAPG)|Market Capitalization to Book Value Ratio URGN|Market Capitalization to Book Value Ratio Bicara Corp (BCAX)|Market Value to Book Value Ratio Personalis, Inc. PSNL|ERAS: Capitalization to Book Value Ratio|Delcath Systems - Market Capitalization to Book Value Ratio|Y-mAbs Therapeutics Inc (YMAB) - Market Cap to Net Assets Ratio|AURA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Candel Therapeutics, Inc. (CADL)|Market Value to Book Value Ratio Accuray Incorporated|SLS: Market Value to Book Value|Market Cap to Net Assets Ratio ACTU (Actuate Therapeutics)|CTOR (Citius Oncology Inc.) - Market Value to Book Value|Market Capitalization to Book Value Ratio HURA (TuHURA Biosciences)|TARA - Market Cap to Net Assets Ratio|FATE: Market Cap to Net Assets Ratio|WHWK - Market Capitalization to Book Value Ratio|tscan.com (TCRX) - Market Value to Book Value Ratio|Champions Oncology, Inc. - Market Value to Book Value|XBIT (XBiotech Inc) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio CEL-SCI Corp CVM|Market Capitalization to Book Value Ratio OSTX|Market Cap to Net Assets Ratio Radiopharm Theranostics Ltd RADX|Market Capitalization to Book Value Ratio ARTV (Artiva Biotherapeutics)|Market Value to Equity Ratio Adlai Nortye Ltd|VERU: Market Cap to Net Assets Ratio|Market Value to Book Value TPST (Tempest Therapeutics Corp)|xiliotx.com (XLO) - Market Value to Book Value Ratio|Market-to-Book Ratio Renovaro (RENB)|Market Value to Book Value Ratio Mural Oncology PLC|Capitalization to Book Value Ratio KAPA (Kairos Pharma Inc)|Market Capitalization to Book Value Ratio OKUR|Market Cap to Net Assets Ratio w2.cytomed.sg GDTC|Market Value to Book Value Ratio Curis CRIS|Apollomics Inc. (APLM) - Market-to-Book Ratio|THAR - Market Value to Book Value Ratio|ADVB: Market Value to Book Value Ratio|Genprex, Inc (GNPX) - Market Value to Book Value Ratio|Market-to-Book Ratio Calidi Biotherapeutics, Inc. (CLDI)|SBFM (Sunshine Biopharma) - Market Capitalization to Book Value Ratio|XBIO - Market Value to Equity Ratio|Market Cap to Net Assets Ratio SLRX (Salarius Pharmaceuticals, Inc.)|PPBT - Market-to-Book Ratio|American Oncology Network, Inc. - Market Cap to Net Assets Ratio|Market Value to Book Value BGNE|Checkpoint Therapeutics - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Elevation Oncology Inc. ELEV|icadmed.com (ICAD) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio IKNA|NTBL (Notable Labs Inc.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Viracta (VIRX)|Market Cap to Net Assets Ratio MOR (MorphoSys AG)|Market Capitalization to Book Value nayabiosciences.com|Market Capitalization to Book Value Ratio AAPGV (Ascentage Pharma)